Whilst I agree with the notion to be cautious in China to...

Whilst I agree with the notion to be cautious in China to protect ones IP, the generalisation of the concept of
Chinese companies simply adopting and copying and move on is beside the actual reality.
I have worked with my companies many years in Asia, 5 of those in China.
There are many processes in place to guarantee a good outcome for foreign companies to do business in China, guess why everybody is doing it?
Consumer market is massive in China, still an untapped place in many areas, look at the middle class developed in the country in the last 15 years alone, nearly the demographic size of Europe.
The advantages outpace the disadvantages by far and companies do put protections in place as the dangers are so commonly known since that you really need to look in detail at the issue to have an educated opinion.

The announcement is potentially huge, let's await the outcome of next month's CACLP, I expect some very interesting news to come out of this.
It might also pay to read the ann carefully, GeneoDx will distribute a specific range of Anteobind products, there has obviously been a body of work put into this, protecting broader Anteo IP .
We do have a distribution company dealing with the domestic market landscape, the only way to move forward in the country as a foreign company. We are also dealing with a large International life science group through a local subsidiary, opening doors even outside the vast domestic market.

The intricacies of the deal/ s won't be known possibly at any time to the broader market but it seems to me that
all the right steps at this point in time are taken to protect our IP and maximize potential.